Table 2 Clinical trials about PARP inhibitor plus chemotherapy
Combination therapy | Trial | Cancer | Phase | Status |
|---|---|---|---|---|
Rucaparib and Cisplatin | NCT01074970 | Breast cancer | 2 | Active, not recruiting |
Olaparib, Paclitaxel, and Carboplatin | NCT03150576 | Breast cancer | 2/3 | Recruiting |
PF-01367338 and Carboplatin | NCT01009190 | Advanced solid tumors | 1 | Completed |
BSI-201 and Irinotecan | NCT01173497 | Breast cancer | 2 | Completed |
BSI-201, Carboplatin, and Gemcitabine | NCT00813956 | Breast cancer | 2 | Completed |
Veliparib and Topotecan Hydrochloride | NCT01012817 | Multiple solid tumors | 1/2 | Active, not recruiting |
Olaparib, Cediranib, and Platinum-based Chemotherapy | NCT02855697 | Ovarian cancer | 1 | Recruiting |
Olaparib and Platinum agents | NCT02489006 | Ovarian cancer | 2 | Recruiting |
Iniparib, Carboplatin, and Gemcitabine | NCT00540358 | Breast cancer | 2 | Completed |
AZD2281 and Liposomal Doxorubicin | NCT00628251 | Ovarian cancer | 2 | Completed |
Olaparib, Temozolomide, and Irinotecan | NCT01858168 | Ewing’s sarcoma | 1 | Recruiting |
BMN-673, Temozolomide, and Irinotecan Hydrochloride | NCT02049593 | Advanced solid tumors | 1 | Active, not recruiting |
AZD2281 and Topotecan | NCT00516438 | Advanced solid tumors | 1 | Completed |
AZD2281 and Gemcitabine | NCT00515866 | Pancreatic cancer | 1 | Completed |
AZD2281 and Dacarbazine | NCT00516802 | Melanoma | 1 | Completed |
Veliparib, VX-970, and Cisplatin | NCT02723864 | Advanced solid tumors | 1 | Recruiting |
Niraparib and Temozolomide | NCT03830918 | Small cell lung cancer | 1/2 | Recruiting |
Rucaparib and Platinum-based Chemotherapy | NCT02855944 | Ovarian cancer | 3 | Recruiting |
BGB-290 and Temozolomide | NCT03914742 | Gliomas | 1/2 | Not yet recruiting |
AZD2281, Carboplatin, and Paclitaxel | NCT00516724 | Multiple solid tumors | 1 | Active, not recruiting |
Talazoparib, Irinotecan, and Temozolomide | NCT02392793 | Childhood solid tumors | 1 | Active, not recruiting |
AZD2281, Cisplatin, and Gemcitabine | NCT00678132 | Solid tumor cancers | 1 | Completed |
Talazoparib and Temozolomide | NCT03672773 | Small cell lung cancer | 2 | Recruiting |
Veliparib and Temozolomide | NCT01139970 | Acute leukemia | 1 | Active, not recruiting |
Veliparib and Doxorubicin | NCT01145430 | Ovarian cancer | 1 | Completed |
Talazoparib and Decitabine | NCT02878785 | Acute leukemia | 1/2 | Recruiting |
Olaparib and Temozolomide | NCT03880019 | Uterine leiomyosarcoma | 2 | Not yet recruiting |
BGB-290 and Temozolomide | NCT03749187 | Gliomas | 1 | Recruiting |
Veliparib, Fluorouracil, and Irinotecan Hydrochloride | NCT02890355 | Pancreatic cancer | 2 | Active, not recruiting |
Olaparib and Temozolomide | NCT03212742 | Gliomas | 1/2 | Recruiting |
ABT-888 and Topotecan Hydrochloride | NCT00553189 | Solid tumors and lymphomas | 1 | Completed |
Olaparib and Temozolomide | NCT01390571 | Glioblastoma | 1 | Completed |
Iniparib, Gemcitabine, and Cisplatin | NCT01086254 | Non-small cell lung cancer | 2 | Completed |
Rucaparib, Docetaxel, and Carboplatin | NCT03442556 | Prostate cancer | 2 | Recruiting |
Veliparib, Carboplatin, and Paclitaxel | NCT00535119 | Advanced solid cancer | 1 | Completed |
Veliparib, Carboplatin, Paclitaxel, and Pemetrexed | NCT02944396 | Non-small cell lung cancer | 1/2 | Active, not recruiting |
Veliparib and Cyclophosphamide | NCT01351909 | Breast cancer | 1 | Active, not recruiting |
ABT-888 and Temozolomide | NCT01009788 | Breast cancer | 2 | Active, not recruiting |
BSI-201, Gemcitabine, and Carboplatin | NCT01045304 | Breast cancer | 2 | Completed |
Veliparib and Temozolomide | NCT03581292 | Glioma | 2 | Recruiting |
BSI-201, Gemcitabine, and Carboplatin | NCT01213381 | Advanced solid tumors | 1 | Completed |
Olaparib, Paclitaxel, Topotecan Hydrochloride, and Doxorubicin | NCT02502266 | Ovarian cancer | 2/3 | Recruiting |
Olaparib and Paclitaxel | NCT02789332 | Breast Cancer | 2 | Recruiting |
Veliparib, Carboplatin, Paclitaxel, and FOLFIRI | NCT02033551 | Solid Tumors | 1 | Completed |
Veliparib, Carboplatin, Cisplatin, Fluorouracil, Hydroxyurea, and Paclitaxel | NCT01711541 | Head and neck cancer | 1/2 | Active, not recruiting |
Veliparib, Gemcitabine, and Carboplatin | NCT02860819 | Testicular germ cell cancer | 2 | Recruiting |
Veliparib, Carboplatin, and Paclitaxel | NCT02264990 | Non-small cell lung cancer | 3 | Active, not recruiting |
Veliparib and Carboplatin | NCT01149083 | Breast cancer | 2 | Active, not recruiting |
Veliparib and Mitomycin C | NCT01017640 | Solid tumors | 1 | Completed |
Veliparib, Paclitaxel, and Cisplatin | NCT01281852 | Cervical cancer | 1 | Completed |
Veliparib, Paclitaxel, Carboplatin, and Bevacizumab, | NCT00989651 | Ovarian cancer | 1 | Active, not recruiting |
ABT-888 and Temozolomide | NCT00994071 | Nervous system tumor | 1 | Completed |
Veliparib and Cisplatin | NCT02595905 | Breast cancer | 2 | Recruiting |
Veliparib, Paclitaxel, and Carboplatin | NCT01366144 | Solid tumors | 1 | Suspended |
Veliparib, Gemcitabine Hydrochloride, and Cisplatin | NCT01585805 | Pancreatic cancer | 2 | Active, not recruiting |
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride | NCT00740805 | Solid tumors or non-hodgkin lymphoma | 1 | Active, not recruiting |
Veliparib, Topotecan Hydrochloride, and Carboplatin | NCT00588991 | Acute leukemia, high-risk myelodysplasia, and myeloproliferative disorders | 1 | Active, not recruiting |
Veliparib, Bendamustine Hydrochloride, and Rituximab | NCT01326702 | Lymphoma, multiple myeloma, solid tumors | 1/2 | Completed |
Veliparib, Cisplatin, and Vinorelbine Ditartrate | NCT01104259 | Breast cancer | 1 | Completed |